


PHARMACEUTICAL 2017

Aeglea BioTherapeutics Inc. Rank 97 of 313







PHARMACEUTICAL 2017



Aeglea BioTherapeutics Inc. Rank 97 of 313

The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 294% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 364% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	66,424
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,965
Liabilities, Non-Current	132
Other Assets	40
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	4,836
Property and Equipment	599
Research and Development	18,143
Revenues	0
Selling, General and Administrative Expense	8,391

Output Variable	Value in 1000 USD
Assets	67,063
Liabilities	4,097
Expenses	26,534
Stockholders Equity	62,966
Net Income	-21,698
Comprehensive Net Income	-21,700
Economic Capital Ratio	-53%